Development of DNA Vaccine Candidate against SARS-CoV-2

Xingyun Wang; Nino Rcheulishvili; Jie Cai; Cong Liu; Fengfei Xie; Xing Hu; Nuo Yang; Mengqi Hou; Dimitri Papukashvili; Yunjiao He; Peng George Wang

doi:10.3390/v14051049

Viruses (May 2022)

Development of DNA Vaccine Candidate against SARS-CoV-2

Xingyun Wang,
Nino Rcheulishvili,
Jie Cai,
Cong Liu,
Fengfei Xie,
Xing Hu,
Nuo Yang,
Mengqi Hou,
Dimitri Papukashvili,
Yunjiao He,
Peng George Wang

Affiliations

Xingyun Wang: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Nino Rcheulishvili: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Jie Cai: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Cong Liu: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Fengfei Xie: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Xing Hu: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Nuo Yang: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Mengqi Hou: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Dimitri Papukashvili: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Yunjiao He: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Peng George Wang: Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China

DOI: https://doi.org/10.3390/v14051049
Journal volume & issue: Vol. 14, no. 5
p. 1049

Abstract

Read online

Despite the existence of various types of vaccines and the involvement of the world’s leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains continue to emerge leading to the need for more vaccines that would elicit protectiveness and safety against the new strains of the virus. Nucleic acid vaccines seem to be the most effective approach in case of a sudden outbreak of infection or the emergence of a new strain as it requires less time than any conventional vaccine development. Hence, in the current study, a DNA vaccine encoding the trimeric prefusion-stabilized ectodomain (S1+S2) of SARS-CoV-2 S-protein was designed by introducing six additional prolines mutation, termed HexaPro. The three-dose regimen of designed DNA vaccine immunization in mice demonstrated the generation of protective antibodies.

Published in Viruses

ISSN: 1999-4915 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: http://www.mdpi.com/journal/viruses

About the journal

Abstract

Keywords